Blood Cancers Today

🎉🚨 BREAKING 🚨🎉 The European Commission has approved odronextamab for the treatment of relapsed or refractory follicular lymphoma and #DLBCL, according to a press release from Regeneron. "Physicians, especially in the community setting, will have an off-the-shelf option that can be administered out-patient, offering the chance for complete remission," Stefano Luminari, MD, of the Università degli Studi di Modena e Reggio Emilia, said in the press release. 📰 Read more: https://buff.ly/3MkzajB

Bortezomib has become a staple treatment for multiple myeloma. But clinicians like Drs. Rahul Banerjee and Gurbakhash Kaur are trying to shift the standard of care from twice-weekly dosing to once-weekly dosing. Learn why in our latest feature ➡️ https://buff.ly/3X1gk62

#DidYouKnow that #HSCT yields long-term overall survival outcomes irrespective of the conditioning regimen for patients with #MDS? Read more about the study led by Christian Niederwieser, MD, of Universitätsklinikum Hamburg Eppendorf. 📰 https://buff.ly/3YPWVaY

From research on pralatrexate to azacitidine, our T-cell lymphoma section editor, Dr. Edward Cliff, tells us what's new in the field! Check out our knowledge hub here ➡️ https://buff.ly/3WiBOuU

Compared with epoetin alfa, treatment with luspatercept improved rates of transfusion independence and hematological improvement in significantly more patients with transfusion-dependent lower-risk #MDS. Read more from the phase III COMMANDS trial ➡ https://buff.ly/3X7bwxp

🎉 Our latest Get to Know is out now! 🎉 We interviewed Amy DeZern, MD, of The Johns Hopkins University School of Medicine, to learn about her journey to becoming a hematologist oncologist and what advice she would give to early-career clinicians! 📰 Read here: https://buff.ly/3Xawuvf

🎉 REGULATORY UPDATE 🎉 The FDA recently approved axatilimab-csfr for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy, according to a press release by Incyte and Syndax Pharmaceuticals, co-developers of the drug. 📰 https://buff.ly/4cDt4G3

A subtype of #MDS features isolated deletion of chromosome 5q, or MDS-del(5q), which affects patient outcomes. Read more from the study led by Maria Julia Montoro, MD, PhD, of Hospital Universitari Vall d'Hebron. 📰 https://buff.ly/3SXNbYu

🎉 The European Commission has granted conditional marketing authorization to epcoritamab for adult patients with relapsed or refractory follicular lymphoma after at least two lines of systemic therapy, according to a press release from AbbVie and Genmab, co-developers of the agent. 📰 https://buff.ly/3SVMUVS

Liso-cel shows efficacy and favorable safety as management for heavily pretreated relapsed or remitting mantle cell lymphoma, according to primary analysis results from the TRANSCEND NHL 001 study led by Michael Wang, MD, of MD Anderson Cancer Center. 📰 https://buff.ly/3yL3Ffs